Abstract
BackgroundMMP and TIMP play an important role in the degradation of extracellular matrix components which are essential for tumor growth, invasion and metastasis. Aim of this research was to assess MMP3 and TIMP3 as prognostic factors among patients with ovarian cancer.ResultsIt was found that high levels of output MMP3 correlated with shortened overall survival time of patients by 9.7 months. In addition, it has been shown that high concentrations of output MMP3 were significantly associated with a shorter disease free time in median concentrations implemented p = 0.0059. Statistically significant dependence has been shown between an average concentration of TIMP3 protein to the overall survival of patients. The higher output concentration of TIMP3, the longer patients’ survival by 8.9 month. In addition, it was found that high TIMP3 concentrations output were associated with a significantly longer disease free duration at a median concentrations p = 0.007.ConclusionPreliminary research shows that output levels of MMP3 and TIMP3 proteins correlate with overall survival of patients. In some cases also time free of illness.
Highlights
Matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinase (TIMPs) play an important role in the degradation of extracellular matrix components which are essential for tumor growth, invasion and metastasis
Comparison of mean the concentrations of metalloproteinase 3 inhibitor (TIMP3) levels demonstrated significantly lower concentrations of the marker in the group of patients with ovarian cancer compared to patients with benign cysts (138 pmol/L; 285 pmol/L), respectively)
Mean Matrix metalloproteinase-3 (MMP3), Human epididymis protein 4 (HE4), and Carbohydrate antigen 125 (CA125) protein levels were significantly higher in the group of patients with ovarian cancer compared to patients with benign ovarian cysts
Summary
MMP and TIMP play an important role in the degradation of extracellular matrix components which are essential for tumor growth, invasion and metastasis. Aim of this research was to assess MMP3 and TIMP3 as prognostic factors among patients with ovarian cancer. In 1989 van Houwelingen was the first to introduce a risk-prediction model for ovarian cancer (PI) [1]. Many researchers have tried to create an ovarian cancer prognostic model based on clinical features. In 2015 Zhang added molecular markers: HER2, KRAS, BRCA1, BRAF and EGFR, as independent prognostic factors to the model based on clinical features [5]. It is currently believed that these two markers complement themselves to the sensitivity and specificity, so that creation of the ROMA algorithm with their contribution has improved the effectiveness of good clinical qualification of patients with ovarian tumor [6, 7]. The Ca 125 marker level have been recognized by some authors as a predictive
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
